Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8728MR)

This product GTTS-WQ8728MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8728MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4889MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ2204MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ10087MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ11179MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
GTTS-WQ1856MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ5247MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ9248MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW